- /
- Supported exchanges
- / US
- / GRI.NASDAQ
GRI Bio Inc. (GRI NASDAQ) stock market data APIs
GRI Bio Inc. Financial Data Overview
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with GRI Bio Inc. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get GRI Bio Inc. data using free add-ons & libraries
Get GRI Bio Inc. Fundamental Data
GRI Bio Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -10 027 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-14
- EPS/Forecast: -1.11
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GRI Bio Inc. News
New
European Undervalued Small Caps With Insider Action For January 2026
As the pan-European STOXX Europe 600 Index edges closer to record highs, buoyed by optimism about future earnings and economic prospects, small-cap stocks in Europe are capturing investor attention am...
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Profusa Inc. 531,709,308 0.1695...
Grainger's (LON:GRI) Upcoming Dividend Will Be Larger Than Last Year's
Grainger plc's (LON:GRI) periodic dividend will be increasing on the 20th of February to £0.0546, with investors receiving 9.0% more than last year's £0.0501. This will take the annual payment to 4....
Exploring 3 Promising Undervalued Small Caps With Insider Buying In Global
As global markets navigate a landscape marked by dovish Federal Reserve comments and subdued economic indicators, small-cap stocks have shown notable resilience, with the Russell 2000 Index outperform...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.